ORIENTBIO Inc. Market Cap ($97.24 Million)
Market Cap & Net Worth: ORIENTBIO Inc. (002630)
ORIENTBIO Inc. market cap. ORIENTBIO Inc. (KO:002630) has a market capitalization of $97.24 Million (₩143.49 Billion) as of November 4, 2026. Listed on the KO stock exchange, this Korea-based company holds position #19126 globally and #929 in its home market, demonstrating a -11.03% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ORIENTBIO Inc.'s stock price ₩1210.00 by its total outstanding shares 118583005 (118.58 Million). Also see 002630 cash flow conversion for how efficiently the company converts equity into cash flow.
ORIENTBIO Inc. Market Cap History (2015–2026)
ORIENTBIO Inc. market cap history from 2015 to 2026. Data shows change from $225.99 Million to $97.24 Million (-6.92% CAGR). Check ORIENTBIO Inc. stock quote for real-time trading data and today's change.
ORIENTBIO Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ORIENTBIO Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ORIENTBIO Inc. (002630) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
ORIENTBIO Inc.'s market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $291.18 Million | $105.05 Billion | -$3.01 Billion | 0.00x | N/A |
| 2017 | $187.75 Million | $109.02 Billion | -$19.13 Billion | 0.00x | N/A |
| 2018 | $102.29 Million | $121.21 Billion | -$13.87 Billion | 0.00x | N/A |
| 2019 | $54.66 Million | $30.37 Billion | -$19.51 Billion | 0.00x | N/A |
| 2020 | $101.66 Million | $37.70 Billion | -$10.88 Billion | 0.00x | N/A |
| 2021 | $98.04 Million | $52.02 Billion | -$15.27 Billion | 0.00x | N/A |
| 2022 | $49.26 Million | $26.28 Billion | $34.20 Billion | 0.00x | 0.00x |
| 2023 | $48.78 Million | $28.82 Billion | -$12.42 Billion | 0.00x | N/A |
| 2024 | $124.32 Million | $28.01 Billion | $12.87 Billion | 0.00x | 0.01x |
| 2025 | $48.30 Million | $29.40 Billion | -$13.19 Billion | 0.00x | N/A |
Competitor Companies of 002630 by Market Capitalization
Companies near ORIENTBIO Inc. in the global market cap rankings as of November 4, 2026. Also see 002630 total assets for a full breakdown of the balance sheet.
Key companies related to ORIENTBIO Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of ORIENTBIO Inc. (2015–2026)
Market capitalization of ORIENTBIO Inc. from 2015 to today. Between 2015 and today, ORIENTBIO Inc.'s market cap moved from $225.99 Million to $ 97.24 Million, with a yearly change of -6.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩97.24 Million | +101.33% |
| 2025 | ₩48.30 Million | -61.15% |
| 2024 | ₩124.32 Million | +154.86% |
| 2023 | ₩48.78 Million | -0.98% |
| 2022 | ₩49.26 Million | -49.75% |
| 2021 | ₩98.04 Million | -3.56% |
| 2020 | ₩101.66 Million | +85.97% |
| 2019 | ₩54.66 Million | -46.56% |
| 2018 | ₩102.29 Million | -45.52% |
| 2017 | ₩187.75 Million | -35.52% |
| 2016 | ₩291.18 Million | +28.85% |
| 2015 | ₩225.99 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of ORIENTBIO Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $97.24 Million USD |
| MoneyControl | $97.24 Million USD |
| MarketWatch | $97.24 Million USD |
| marketcap.company | $97.24 Million USD |
| Reuters | $97.24 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ORIENTBIO Inc.
ORIENT BIO Inc. operates in the bio-industry in South Korea and internationally. It engages in the production, export, import, and life science-related research and development of laboratory animals; and offers various equipment for research environment. The company also provides infrastructural solution; health checking; generic testing; molecular biological generic testing; generic transformati… Read more